#Class Action #Faruqi & Faruqi #Telix Pharmaceuticals

Faruqi & Faruqi Encourages Telix Investors to Take Action

The law firm Faruqi & Faruqi, LLP, well-known for handling securities litigation, has recently issued a reminder to investors of Telix Pharmaceuticals Limited regarding a pending class action lawsuit. The deadline for the nomination of a lead plaintiff is set for January 9, 2026, making it crucial for affected investors to become involved.

Background of the Case

Faruqi & Faruqi's Partner, James (Josh) Wilson, has called upon investors who acquired Telix securities between February 21 and August 28, 2025, to reach out for a discussion about their legal options. This class action lawsuit arises from allegations that the company, along with its executives, violated federal securities laws by making misleading statements about its prostate cancer therapeutic candidates and the overall health of its supply chain.

The firm has a track record of recovering substantial amounts for investors since its inception in 1995. The claims underpinning this suit allege that Telix has materially overstated its progress and misrepresented the reliability of its operations. In essence, when the truth about Telix's business situation came to light, many investors faced significant financial losses.

Timeline of Events

The difficulties faced by Telix Pharmaceuticals were exacerbated on July 22, 2025, when the company disclosed that it had received a subpoena from the U.S. Securities and Exchange Commission (SEC). The subpoena sought various documents related to its disclosures concerning the development of its prostate cancer therapeutics candidates. Not surprisingly, such revelations led to an approximate 13% decline in the trading price of Telix's American Depositary Shares (ADS) over the subsequent two trading days.

Further compounding the situation, on August 28, 2025, Telix announced that it had received a Complete Response Letter from the FDA regarding its product TLX250-CDx. This letter identified several